Fennec Pharmaceuticals Inc. (TSE:FRX – Get Free Report) Director Rostislav Christov Raykov sold 9,747 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of C$13.23, for a total transaction of C$128,952.81. Following the completion of the transaction, the director owned 2,746,104 shares of the company’s stock, valued at approximately C$36,330,955.92. The trade was a 0.35% decrease in their ownership of the stock.
Rostislav Christov Raykov also recently made the following trade(s):
- On Monday, June 1st, Rostislav Christov Raykov bought 15,597 shares of Fennec Pharmaceuticals stock. The shares were acquired at an average price of C$3.37 per share, for a total transaction of C$52,561.89.
Fennec Pharmaceuticals Price Performance
FRX remained flat at C$12.72 during trading on Thursday. The company’s stock had a trading volume of 1,030 shares, compared to its average volume of 1,286. The firm has a market cap of C$441.85 million, a PE ratio of -43.86 and a beta of 3.52. Fennec Pharmaceuticals Inc. has a 1-year low of C$7.59 and a 1-year high of C$14.24. The business’s 50-day moving average is C$10.30 and its 200 day moving average is C$10.62.
Wall Street Analysts Forecast Growth
Get Our Latest Stock Analysis on FRX
Fennec Pharmaceuticals Company Profile
Fennec Pharmaceuticals Inc is a specialty pharmaceutical company committed to the fight against ototoxicity in cancer patients who receive cisplatin-based chemotherapy. Fennec is focused on the commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in cancer patients. PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and United Kingdom ( U.K. ) approval in October 2023 under the brand name PEDMARQSI®. In March 2024, Fennec entered into an exclusive licensing agreement under which Norgine Pharmaceuticals Ltd., a leading European specialist pharmaceutical company, with rights to commercialize PEDMARQSI® in Europe, U.K., Australia and New Zealand.
Featured Stories
- Five stocks we like better than Fennec Pharmaceuticals
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Fennec Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fennec Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
